SCHEMBL7045566

SCHEMBL7045566

CS(=O)(=O)Nc1cc2cccnc2c(N2CCNCC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKD1 Q15139 1/20 0.49
▸ HTR2C P28335 2/20 0.46
▸ HTR2A P28223 2/20 0.46
▸ SLC6A4 P31645 1/20 0.46
▸ ALOX15 P16050 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ GLO1 Q04760 1/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ EPHX2 P34913 1/20 0.40
▸ PIK3R1 P27986 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ HTR6 P50406 2/20 0.39
▸ HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045097 0.85 SLC40A1 (0.49) PRKD1HTR2CHTR2ASLC6A4GLO1
SCHEMBL1379328 0.85 TDP1 (0.50) PRKD1HTTLMNAHTR6
SCHEMBL3619544 0.84 PRKD1 (0.44) PRKD1HTR2CHTR2ASLC6A4GLO1
SCHEMBL1380902 0.84 GLO1 (0.51) PRKD1HTR2CHTR2ASLC6A4GLO1
SCHEMBL3616470 0.83 MEN1 (0.50) PRKD1HTR2CHTR2ASLC6A4ALOX15
SCHEMBL1380555 0.82 NFKBIA (0.51) PRKD1HTR2CHTR2ASLC6A4ALOX15
SCHEMBL3616367 0.82 HTR6 (0.51) PRKD1HTR2CHTR2ASLC6A4CYP3A4
SCHEMBL10571731 0.81 PRKD1 (0.49) PRKD1HTR2CHTR2ASLC6A4EPHX2
SCHEMBL3627476 0.81 MEN1 (0.53) MAPK1HTR6HTR7
SCHEMBL1377405 0.80 SLC40A1 (0.54) PRKD1CYP3A4HTR6HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 — — EP disclosed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 — — WO disclosed
Send feedback